StockMarketWire.com - Veterinary medicines supplier Animalcare Group's revenues for the year to the end of June were about 5% up on last time.

It says the four new products launched in the year, along with those launched in late 2009-10, contributed substantially to this growth, which was also underpinned by a strong performance in the group's existing ranges, notably fluid therapy and database services.

Earnings from continuing operations will again show a good progression from last year and are expected to be in line with market expectations.

Animalcare also said it had received notification from the Swedish pharmaceutical contract manufacturing group Recipharm that it will close its steriles production unit at the Recipharm Ashton facility with immediate effect.

Due to ongoing production issues this unit had originally been scheduled to close in June 2012.

Ashton produces the 1ml ampoule version of Animalcare's buprenorphine based analgesic, Buprecare.

This is the only product supplied to Animalcare from Ashton.

Animalcare said it was in the process of establishing alternative manufacturing for Buprecare ahead of the scheduled closure of Ashton steriles production.

Efforts are being made to accelerate the plans already in place to switch production of the Buprecare 1ml ampoule product to an alternative supplier.

Unfortunately the premature closure means that there now will be a period during which Animalcare will be unable to supply the 1ml ampoule presentation of Buprecare to the UK market.

The supply position for the European markets is stronger and any disruption is expected to be minor.






At 9:16am: [LON:ANCR] share price was -6p at 170p



Story provided by StockMarketWire.com